In SURMOUNT1, tirzepatide shifted body composition and cardiometabolic markers in ways that support strength, mobility, and longterm resilience. Researchers from the SURMOUNT1 program found that tirzepatide was associated with: Average weight loss of about 1521% of starting body weight at higher doses Reductions in waist circumference of roughly 1420 cm, signaling less central and visceral fat About threequarters of weight lost coming from fat mass, with fat mass dropping by around onethird and lean mass by about 10% Meaningful drops in systolic blood pressure and atherogenic lipids, with more participants hitting combined goals for weight, blood pressure, and nonHDL cholesterol versus placebo Improved physical function scores on questionnaires, reflecting easier walking, stair climbing, and daily activity That pattern preferential fat loss, preserved muscle, a smaller waist, and better hemodynamics is exactly what protects balance, strength, and independence, making it one of the clearest ways tirzepatide can support a longer healthspan beyond a lower number on the scale
Melanotan II is a synthetic analogue of the peptide hormone -melanocyte-stimulating hormone (-MSH) that stimulates melanogenesis to facilitate tanning
How does NAD help with cancer, intestinal and age-related diseases
The same is true for NSAIDs (ketoconazole and lysophylline), statins and albuterol, for example [45]
Significant weight loss results may take several months
